A Phase 1 interventional study of Ritlecitinib and Tolbutamide in Healthy Volunteers, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-06.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 1, 2-period, multiple-dose, open-label, single fixed sequence study of the effect of ritlecitinib on tolbutamide pharmacokinetics in healthy participants.
A total of approximately 12 healthy male and/or female participants will be enrolled in the study to obtain at least 10 evaluable participants who complete the study. This is an open-label study not requiring an assessment of efficacy or pharmacodynamics markers, but it will include pharmacokinetic estimation drug-drug interactions.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Period 1, participants will be dosed with a single administration of tolbutamide 500 mg tablet on Day 1. Period 1 will be immediately followed by Period 2 with no washout. In Period 2, participants will be dosed with oral 200 mg ritlecitinib QD for 10 days followed by administration of a single dose of 500 mg tolbutamide oral tablet within approximately 5 minutes after administration of a 200 mg dose of ritlecitinib on the morning of Day 10.
Drug: Ritlecitinib · Drug: Tolbutamide
Ritlecitinib 200 mg provided as four 50 mg oral capsules
Also known as: PF-06651600
Tolbutamide 500 mg provided as one 500 mg oral tablet
Maximum Plasma Concentration (Cmax) of Tolbutamide Administered With and Without Ritlecitinib
Cmax was defined as maximum observed plasma concentration. The determination method of Cmax was observing directly from data.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, and 36 hours post-dose of tolbutamide in Period 1 (Days 1 and 2) and Period 2 (Days 10 and 11)
Area Under the Plasma Concentration Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Tolbutamide Administered With and Without Ritlecitinib
AUCinf was defined as area under the plasma concentration time profile from time 0 extrapolated to infinite time.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, and 36 hours post-dose in Period 1 (Days 1 and 2) and Period 2 (Days 10 and 11)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) - All Causalities and Treatment Related
An adverse event (AE) was any untoward medical occurrence in a clinical investigation where participants were administered a product; the event needed not necessarily have a causal relationship with the treatment or usage. TEAEs were events between first dose of study drug and up to discharge from study that were absent before treatment or that worsened relative to pretreatment state. A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug.
Time frame: From screening up to a follow-up phone call between 28 and 35 calendar days after the last administration of the investigational product and early termination (if applicable)
| Milestone | Period 1: Tolbutamide and Period 2: Ritlecitinib + Tolbutamide |
|---|---|
| Started | 12 |
| Completed | 10 |
| Not completed | 2 |
| Withdrew: Adverse event | 1 |
| Withdrew: Close contact with highly-transmissible infection | 1 |
| Milestone | Period 1: Tolbutamide and Period 2: Ritlecitinib + Tolbutamide |
|---|---|
| Started | 10 |
| Completed | 10 |
| Not completed | 0 |
Cmax was defined as maximum observed plasma concentration. The determination method of Cmax was observing directly from data.
| ng/mL (nanogram/milliliter) | Period 1: Tolbutamide | Period 2: Ritlecitinib + Tolbutamide |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of Tolbutamide Administered With and Without Ritlecitinib | 44240 ± 15 | 45740 ± 17 |
AUCinf was defined as area under the plasma concentration time profile from time 0 extrapolated to infinite time.
| ng*hr/mL | Period 1: Tolbutamide | Period 2: Ritlecitinib + Tolbutamide |
|---|---|---|
| Area Under the Plasma Concentration Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Tolbutamide Administered With and Without Ritlecitinib | 608600 ± 20 | 586500 ± 30 |
An adverse event (AE) was any untoward medical occurrence in a clinical investigation where participants were administered a product; the event needed not necessarily have a causal relationship with the treatment or usage. TEAEs were events between first dose of study drug and up to discharge from study that were absent before treatment or that worsened relative to pretreatment state. A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug.
| Participants | Period 1: Tolbutamide | Period 2: Ritlecitinib | Period 2: Ritlecitinib + Tolbutamide |
|---|---|---|---|
| All-Causality | 1 | 2 | 2 |
| Treatment-Related | 0 | 0 | 1 |
Collected over From screening up to a follow-up phone call between 28 and 35 calendar days after the last administration of the investigational product and early termination (if applicable). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period 1: Tolbutamide | 0/12 (0%) | 0/12 (0%) | 1/12 (8.3%) |
| Period 2: Ritlecitinib | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Period 2: Ritlecitinib + Tolbutamide | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Event | Period 1: Tolbutamide | Period 2: Ritlecitinib | Period 2: Ritlecitinib + Tolbutamide |
|---|---|---|---|
| PainGeneral disorders | 0/12 | 1/10 | 0/10 |
| COVID-19Infections and infestations | 1/12 | 0/10 | 1/10 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/12 | 0/10 | 1/10 |
| Nail disorderSkin and subcutaneous tissue disorders | 0/12 | 1/10 | 0/10 |
Baseline analysis population included all participants assigned to the study intervention.
| Age, Continuous(Years) | Male | Female | Total |
|---|---|---|---|
| Mean | 37.4 ± 12.57 | 48.7 ± 11.15 | 40.3 ± 12.78 |
| Age, Continuous(Years) | Male | Female | Total |
|---|---|---|---|
| Median | 36.0 (23.0 to 57.0) | 53.0 (36.0 to 57.0) | 37.0 (23.0 to 57.0) |
| Age, Customized(Participants) | Male | Female | Total |
|---|---|---|---|
| <18 | 0 | 0 | 0 |
| 18-44 | 6 | 1 | 7 |
| 45-64 | 3 | 2 | 5 |
| >=65 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Male | Female | Total |
|---|---|---|---|
| Female | 0 | 3 | 3 |
| Male | 9 | 0 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Male | Female | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 8 | 2 | 10 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Male | Female | Total |
|---|---|---|---|
| White | 5 | 2 | 7 |
| Black or African American | 4 | 0 | 4 |
| Asian | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Nov 2021 to primary completion in Jan 2022, 2 months.
Results were first posted in Oct 2023, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: PF-06651600 · Tolbutamide